MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study[J]. Lancet Oncol. 2020 Mar;21(3):373-386.
[8]pJ. Yang, et al. Osimertinib With or Without Savolitinib as 1L in De Novo MET Aberrant, EGFRm Advanced NSCLC (CTONG 2008): A Phase II Trial. 2024 WCLC, PL04.10. [9]H. Horinouchi ,et al. Telisotuzum...
2.Y. Wu, J. Zhao, J. Hu,etc.388P - Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study[J].ESMO Asia Congress 2022.3. 牛娜.非小细胞肺癌 ＭＥＴ基因...
“世界癌症日”是由国际抗癌联盟(UICC)与世界卫生组织(WHO)联合发起的肿瘤防治公益活动,活动定于每年2月4日。为缩小全球各地癌症医疗服务方面存在的差距,UICC于2022~2024年推出了“整合卫生资源,医疗人人共享”主题活动,今年是该主题的最后一年。作为临床最常见的肿瘤,近年来,肺癌治疗在精准医学的发展下呈现出全新面貌...
[8]https://oncologypro.esmo.org/meeting-resources/esmo-congress/preliminary-results-of-phase-ii-kunpeng-study-of-vebreltinib-in-patients-pts-with-advanced-nsclc-harboring-c-met-alterations.
1、 MA06.11 Phase II Trial of Ensartinib for Advanced or Metastatic Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations 这是一项单臂、多中心、II期研究(ChiCTR2100048767)。入组患者至少接受过一次含铂化疗。从2021年7月至2024年2月,纳入31例患者接受恩沙替尼治疗。
[7]Sequist LV, Han JY, Ahn MJ, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020 ...
6.NCCN NSCLC临床指南非小细胞肺癌.2024.v1. 7.Sequist LV,Han JY,Ahn MJ,et al.Osimertinib plus savolitinib in patients with EGFR mutation-positive,MET-amplified,non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors:interim results from a multicentre,open-label,phase 1...
6.NCCN NSCLC临床指南非小细胞肺癌.2024.v1. 7.Sequist LV,Han JY,Ahn MJ,et al.Osimertinib plus savolitinib in patients with EGFR mutation-positive,MET-amplified,non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors:interim results from a multicentre,open-label,phase 1...
194MO -Phase II study of low-dose radiation (LDRT) plus durvalumab (D) and etoposide/platinum (EP) as first-line treatment in ES-SCLC (LEAD): efficacy and safety results 2期LEAD研究:低剂量放疗 (LDRT) +度伐利尤单抗(D) 和依托泊苷/铂 (EP) 一线治疗ES-SCLC的疗效和安全性汇报人:四川大...